Submit the form to download your free Whitepaper.
Genomics has upended cancer treatment. Where tumors were once categorized by organ, they’re now targeted by mutation ,regardless of anatomical origin. This precision is transformative, but it creates a structural problem: eligible patient populations for trials are tiny and globally scattered, making the classical Phase III RCT increasingly obsolete for biomarkers present in just 1% of solid tumors.
New trial architectures have emerged in response ,basket and umbrella trials that match therapies to mutations across or within tumor types. Elegant in design, they demand data precision and regulatory foresight that traditional CROs weren’t built to deliver.
A second gap compounds the first: regulatory approval and market access are diverging. Payers and HTA bodies remain unconvinced by single-arm trials of twenty patients, continuing to demand comparative evidence that small-population trials rarely generate.
The path forward is a Total Evidence approach- synthetic control arms built from real-world data replacing ethically fraught placebo arms, and HEOR endpoints integrated from Phase II onward rather than bolted on after approval.
At Vigilare BioPharma, one conviction drives this work: safety data, clinical data, and market access data are not separate stories. They are one. Organizations that unify these threads from trial inception are the ones that will actually get therapies to patients.
Comments are closed